News
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal ...
Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer ...
The α-factor receptor of the yeast Saccharomyces cerevisiae encoded by the STE2 gene is a member of the large family of G protein-coupled receptors (GPCRs) that mediate multiple signal transduction ...
We conclude that intracellular Ang II binds to intracellular Ang II receptors and elicits an increased [Ca 2+] i in the injected cell and, thereafter, cells in the immediate neighborhood. Cell-cell ...
A breakthrough in the understanding of how mammals create red blood cells could lead to opportunities for artificial blood to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results